Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.
about
Recent advances of novel targeted therapy in non-small cell lung cancerIcotinib is an active treatment of non-small-cell lung cancer: a retrospective study2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung CancerTranslatability scoring in drug development: eight case studiesThird-line systemic treatment for non-small cell lung cancerClinical use of crizotinib for the treatment of non-small cell lung cancerOptimizing the management of advanced non-small-cell lung cancer: a personal viewRole of gefitinib in the targeted treatment of non-small-cell lung cancer in Chinese patientsMolecular targeted therapy to improve radiotherapeutic outcomes for non-small cell lung carcinomaPulmonary Toxicities of Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled TrialsChina experts consensus on icotinib for non-small cell lung cancer treatment (2015 version)China experts consensus on icotinib for non-small cell lung cancer treatment (2015 version)Identifying activating mutations in the EGFR gene: prognostic and therapeutic implications in non-small cell lung cancerIs there a role for epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor wild-type non-small cell lung cancer?Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what's new and what's enoughChina Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment (2015 version)Novel approaches of chemoradiotherapy in unresectable stage IIIA and stage IIIB non-small cell lung cancerK-Ras Mutations in Non-Small-Cell Lung Cancer: Prognostic and Predictive ValuePostprogression survival for first-line chemotherapy of patients with advanced non-small-cell lung cancerCombining targeted agents and hypo- and hyper-fractionated radiotherapy in NSCLCEGFR mutations as a prognostic and predictive marker in non-small-cell lung cancerSecond-Line Therapy for Advanced NSCLCNon-Small Cell Lung Cancer beyond Biomarkers: The Evolving Landscape of Clinical Trial DesignThe role of irreversible HER family inhibition in the treatment of patients with non-small cell lung cancerUse of the epidermal growth factor receptor inhibitors gefitinib, erlotinib, afatinib, dacomitinib, and icotinib in the treatment of non-small-cell lung cancer: a systematic reviewTargeted therapies in development for non-small cell lung cancerRole of survival post-progression in phase III trials of systemic chemotherapy in advanced non-small-cell lung cancer: a systematic reviewAdvances of molecular subtype and targeted therapy of lung cancerMolecular pathology of lung cancer: key to personalized medicine.EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer.A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFRChina Experts Consensus on the Diagnosis and Treatment of Advanced Stage Primary Lung Cancer (2016 Version)Promising targets and current clinical trials in metastatic squamous cell lung cancerEpidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC)PharmGKB summary: very important pharmacogene information for the epidermal growth factor receptorNovel insights into the molecular origins and treatment of lung cancerEGFR-TKI resistance in NSCLC patients: mechanisms and strategiesPleural LDH as a prognostic marker in adenocarcinoma lung with malignant pleural effusionNivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
P2860
Q21092930-C7DBDC22-C76A-46FA-ABF5-0E613E66BA34Q21132047-484F7818-98B1-4C87-892F-922531DE7E52Q22241671-F14AC178-143B-4BC8-B13B-099C68BDE15AQ22241760-E2D5424E-7290-4184-A668-3EEEFFF86A5DQ24194090-392741F4-93D9-4BCA-B4DA-FAB79ABADC88Q24630466-A9F0AD07-4389-4EFA-B159-D962AD34DA96Q24656144-18D95314-0A7A-48E4-A58F-3E189551C584Q26750428-FDDF3529-C691-4070-B0DA-74167D9B51A9Q26767182-043D7BE4-6DC9-45A9-9C33-0B484E0D0537Q26768125-49DC4896-34D4-4FFB-9736-76EF6564675DQ26775603-324881FE-405D-4E28-B39D-06D36D229E46Q26775677-6F61A18F-CF43-4C3A-BA02-D45518A41A68Q26781810-B440B10F-283C-4BE9-90B0-9F9D75A532CBQ26798882-99B1041B-9566-412C-9072-1DEA99114780Q26799467-F5779475-183C-4388-AE1B-3E3B8940C5D5Q26800148-1D07876F-A7B6-407D-9CFC-B64085B970DBQ26827571-68CDA6BC-9190-4346-BDC4-F71E472797FFQ26829425-CEFCC531-070D-4892-B848-6600A3280C96Q26829939-6D774FE9-04DD-4372-A089-3830F04C050DQ26852202-599A097F-11FD-440A-A0E7-B37BDB3278BCQ26852507-AF0B9B4F-BE17-41F5-A7C6-7896AF60CA6DQ27002398-F16A6678-5379-4A31-A3CD-04AEB260D5EDQ27003440-34AB5294-0A86-4D6F-800B-A36F2C2FADD5Q27021738-24606AB8-89BA-4798-8152-2842E4F4AA8EQ27022535-5EC981F2-1A6F-43AA-8B62-FCE9B4C1B2ECQ27022852-A7DCDF6A-4422-450B-9B5C-28A370538F7BQ27025724-19820A56-2F74-42ED-AA98-C0365139C10CQ27030813-BE1FFFC4-AFB8-4383-A64F-A9787B579D9DQ27691299-BCD328F2-31C9-43D1-AD8B-E2F987085A7EQ27851583-E6D7B822-AA2F-4BA9-B254-035F4FE62FBDQ27851729-B189550A-A3C4-45F2-9A0B-619CC965BCC3Q27851872-E5B15E02-8A03-4B53-98FA-62A787FB427EQ28073920-3306EFFB-1766-4225-B442-4B471AA9E362Q28083663-B00D0002-C796-4E7F-A3FC-F2101C82B377Q28284519-43EB00FC-6565-4423-922E-AD000DACAB8EQ28382921-ECC296EF-41CA-405E-8814-6F6CC6CADAEDQ28386773-40D6B449-7A1E-49C2-9C56-70A459A3EA40Q28394310-FA148C11-1B3B-4AF7-9F2A-0C58D0CA1DB2Q28830889-D6968758-BAFD-454A-958E-490363B74B97Q29620902-C7931B65-28EA-4791-8E2E-897F497377BE
P2860
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Gefitinib versus docetaxel in ...... a randomised phase III trial.
@en
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer
@nl
type
label
Gefitinib versus docetaxel in ...... a randomised phase III trial.
@en
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer
@nl
prefLabel
Gefitinib versus docetaxel in ...... a randomised phase III trial.
@en
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer
@nl
P2093
P50
P1433
P1476
Gefitinib versus docetaxel in ...... : a randomised phase III trial
@en
P2093
Alison A Armour
Claire L Watkins
Edward S Kim
Elizabeth S Lowe
Frances A Shepherd
Kell Osterlind
Long-Yun Li
Mark A Socinski
Mark V Sellers
Martin Reck
P304
P356
10.1016/S0140-6736(08)61758-4
P407
P577
2008-11-01T00:00:00Z